Related Experiment Video
Updated: Jun 26, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
C-type natriuretic peptide in prostate cancer
Soeren Junge Nielsen1, Peter Iversen, Jens F Rehfeld
1Department of Clinical Biochemistry, Ringhospitalet, University of Copenhagen, Denmark.
Summary
C-type natriuretic peptide (CNP) is present in human prostate cancer tissue and epithelial cells. While plasma levels showed minor differences in prostate cancer patients, CNP is not a reliable cancer marker.
Area of Science:
- Endocrinology
- Urology
- Oncology
Background:
- C-type natriuretic peptide (CNP) is known to be expressed in male reproductive organs in pigs.
- The expression and role of CNP in the human prostate, particularly in the context of cancer, remain largely uncharacterized.
Purpose of the Study:
- To investigate the expression of the C-type natriuretic peptide (CNP) gene in the human prostate.
- To quantify CNP and N-terminal proCNP levels in prostate cancer tissue and plasma.
- To evaluate the potential of proCNP-derived peptides as biomarkers for prostate cancer.
Main Methods:
- Measurement of N-terminal proCNP, proCNP (1-50), and CNP in tissue extracts from human prostate cancer biopsies.
- Immunohistochemical staining of prostatic biopsies to detect CNP-22 and N-terminal proCNP.
- Quantitation of N-terminal proCNP concentrations in plasma samples from patients with localized prostate cancer and healthy controls.
Main Results:
- Human prostate cancer tissue extracts predominantly contained N-terminal proCNP, with significantly lower levels of mature CNP.
- Immunohistochemistry confirmed the presence of CNP-22 and N-terminal proCNP within prostatic epithelial cells.
- Plasma N-terminal proCNP concentrations were marginally lower in localized prostate cancer patients compared to controls, but the difference was not clinically significant for cancer detection.
Conclusions:
- The human prostate expresses CNP, primarily in the form of N-terminal proCNP within epithelial cells.
- Current evidence does not support the use of plasma N-terminal proCNP as a reliable biomarker for diagnosing localized prostate cancer.
- Further research is warranted to explore the clinical utility of proCNP-derived peptides in prostate cancer management.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...